Related Experiment Video
Updated: May 17, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
Bone mineral density increases in HIV-infected children treated with long-term combination antiretroviral therapy
Madeleine J Bunders1, Olivier Frinking, Henriette J Scherpbier
1Department of Paediatric Immunology, Haematology, and Infectious Diseases, Emma Children Hospital, Amsterdam, The Netherlands. m.j.bunders@amc.uva.nl
Insights
Combination antiretroviral therapy (cART) for children with human immunodeficiency virus (HIV) may affect bone health. Long-term data reveal that cumulative cART positively impacts bone mineral density (BMD) over time in these children.
Area of Science:
- Pediatrics
- Infectious Diseases
- Endocrinology
Background:
- Long-term management of human immunodeficiency virus (HIV) in children involves combination antiretroviral therapy (cART).
- Potential adverse effects of cART, including impacts on bone health, require ongoing evaluation.
- Osteoporosis is a significant concern in HIV-infected populations.
Purpose of the Study:
- To assess the long-term effects of combination antiretroviral therapy (cART) on bone mineral density (BMD) in children with HIV.
- To evaluate the relationship between cumulative cART exposure and BMD changes over time.
Main Methods:
- Longitudinal study design.
- Collection and analysis of bone mineral density (BMD) data in HIV-infected children.
- Assessment of cumulative combination antiretroviral therapy (cART) exposure.
Main Results:
- Longitudinal data demonstrated a positive impact of cumulative cART on bone mineral density (BMD) over time.
- Analysis indicated that extended treatment with cART is associated with improved BMD in HIV-infected children.
Conclusions:
- Combination antiretroviral therapy (cART) appears to have a beneficial effect on bone mineral density (BMD) in children with HIV.
- Long-term cART may mitigate some of the bone-related adverse effects in pediatric HIV infection.
Abstract:
The long-term treatment of human immunodeficiency virus (HIV)-infected children with combination antiretroviral therapy (cART) requires assessment of potential adverse effects, such as osteoporosis. Longitudinal data on bone mineral density (BMD) in HIV-infected children showed that cumulative treatment with cART had a positive impact on BMD over time.
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Retrovirus Life Cycles
Sexually Transmitted Infections
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Pharmacokinetics in Pediatric Patients: Drug Excretion
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
